# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹1,400 Cr Q3 (+22% YoY) · ₹4,900 Cr 9M (+12% YoY) * Adjusted EBITDA: ₹4,490 Cr Q3 (+25% YoY, 26% margin) · ₹11,582 Cr 9M (25% margin) * **Net Profit:** ₹227 Cr 9M (14% adjusted PAT margin) * **Cenexi Revenue:** €50 Mn Q3 (+21% CC) · €138 Mn 9M (+14% CC) * **Cash & Equivalents:** ₹3,500 Cr (as of Dec 31, 2025) ## B. Revenue Growth * **Broad-Based Momentum:** Strong double-digit top-line growth driven by robust performance across all geographies and businesses, with Europe up sharply and U.S. showing solid expansion. * **Cenexi Acceleration:** Cenexi delivered **39% YoY revenue growth** in Q3, reflecting successful integration and strong client demand in the CDMO segment. * **Sustainable Growth Trajectory:** Management views current revenue levels as a new base for future quarters, supported by volume gains rather than one-time factors. ## C. EBITDA & Margins * **Margin Resilience:** Adjusted EBITDA margin held firm at 26% despite higher R&D and ESOP-related expenses, aided by operating leverage and cost efficiency programs. * **Cenexi Turnaround Complete:** Cenexi achieved **breakeven EBITDA** and delivered **positive quarterly EBITDA of ₹8 crore**, marking a full operational recovery. * **Cost Discipline:** Internal efficiency initiatives — including yield improvements, alternate sourcing, and automation — delivered **100–200 bps of margin benefit**, offsetting pricing pressure. * **Base Business Strength:** Excluding Cenexi, base business maintained **37% EBITDA margins** on 16% revenue growth, demonstrating pricing discipline and portfolio optimization. ## D. Net Profit & Tax * **PAT Margin Expansion:** Adjusted PAT margin improved to 16% in Q3 and 14% for 9M, reflecting operating leverage and effective tax management. * **ESOP Impact:** Current quarter ESOP expense was **₹14 crore**, with full-year impact elevated due to mid-quarter grant timing; future grants may increase outlays. ## E. Cash Flow & Liquidity * **Healthy Cash Generation:** Cash flow from operations totaled **₹707 crore in 9M**, supporting self-funded growth and strong liquidity. * **Working Capital Improvement:** Cash conversion cycle improved to **166 days** from 172 days, driven by tighter inventory and receivables control. --- # 2. Product & Therapy Performance ## A. Key Figures * **Liraglutide Launch:** U.S. launch completed in January · Canada launched last quarter * **Dalba Expansion:** Approved and launched in **6 European countries** as of December * **CDMO Oncology Contract:** Expected to generate **$25–30M annual revenue**, commercialization in Q3/Q4 FY28 * **Bags Portfolio:** **20 products filed**, **16 approved**, targeting **$685M market opportunity** * Joint Tenders: Two global ampoule tenders of 60–70 million ampoules, with ~70% from Gland ## B. GLP-1 & Cartridge Launches * **C. S. Market Entry Achieved:** Liraglutide launch in the U.S. marks a major commercial milestone, with additional GLP-1 partnerships in active negotiation. * **Pipeline Diversification:** Strategic expansion beyond liraglutide into **semaglutide generics** and advanced talks with a **major insulin player**, signaling shift toward high-value metabolic therapies. * **Cartridge Growth Trajectory:** New line poised for material revenue inflection in FY28, driven by potential **insulin partnership with big pharma** and a robust funnel of GLP-1 customers. ## C. Bags & Ophthalmic Portfolio * **Bags Portfolio Momentum:** Advanced stage of development with strong regulatory progress—**13 under development**, **16 approved**—targeting a near-$700M market. * **Ophthalmic Capacity Expansion:** New suspension-capable line in development to address unmet demand and support pipeline approvals, closing a key capability gap. * **Cenexi Innovation Ramp-Up:** Sales growing for **inactivated vaccine** and **sterile ophthalmic gel**, both innovative products showing sustained quarter-on-quarter momentum. ## D. CDMO Contract Wins * **High-Value CDMO Traction:** Secured long-term contracts in **oncology, peptides, and prefilled syringes** with large pharma, enabling durable revenue and value-led growth shift. * **Cross-Selling & Integration Paying Off:** Fully integrated BD teams with Cenexi driving joint tenders and cross-capacity utilization, particularly for European manufacturing access. * **New Revenue Models Emerge:** In-licensing of Gland products by Cenexi CDMO clients generating milestone income, with **4 products licensed in Europe last quarter**. * **Strategic Capability Synergy:** Cenexi’s expertise in **herbal and controlled substances** unlocks new revenue streams from Gland’s base business, enhancing portfolio value. --- # 3. Geography & Market Mix ## A. Key Figures * **B. S. Revenue:** ₹829 Cr Q3 (+16% YoY) · ₹2,600 Cr 9M * **Europe & Canada Revenue:** ₹109 Cr Q3 (+16% YoY) · ₹396 Cr 9M (+17% YoY) * **Rest of World Revenue:** ₹60 Cr Q3 (+12%) · ₹400 Cr 9M (+5%) * **India Revenue:** ₹40 Cr Q3 (+32% YoY) · ₹200 Cr 9M (6% of base) ## B. U.S. Market Trends * **Robust U.S. Momentum:** Strong double-digit revenue growth driven by **9 new molecule launches** (e.g., Argatroban, Acetazolamide) and increased volume from GPO contracts for top 10 products. * **Diversification Push:** Despite U.S. contributing **50% of total revenue**, strategic shift underway to reduce over-reliance, with active portfolio expansion and geographic rebalancing. * **Underlying Base Resilience:** Base business in U.S. and Europe grew at **~5% constant currency**, indicating stable demand trends amid market normalization. ## C. Europe & Canada Growth * **Synergy-Led Expansion:** European growth accelerated by Cenexi-Gland integration, enabling new market entries via **licensed product launches** and active dossier filings. * **Sustained Ramp-Up:** Strong quarterly performance in Gland’s Europe business reflects **positive momentum in key products**, signaling durable growth trajectory. ## D. Rest of World Expansion * **CMO-Led Outperformance:** RoW revenue growth outpaced volumes, with **tech transfer CMO revenue surging 44%**, highlighting growing manufacturing partnerships. ## E. India Revenue Uptick * **Disproportionate Growth:** India delivered the strongest YoY revenue increase, with **Q3 growth at 32%**, significantly outperforming overall base business. --- # 4. Manufacturing & Capacity ## A. Key Figures * Cartridge Fill-Finish Capacity: 40 Mn → 140 Mn units (expansion underway) · +100 Mn units in 5 months * **Capex Plan:** **₹2,000 Cr** over 5 years for BFS, ophthalmic lines, and CDMO support · **₹80 Cr** for specific infrastructure setup * **Biologic CDMO Capacity:** Expanding from **8 KL to 23 KL** (**tripling**) with contracts secured ## B. Fill-Finish Expansion * **Strategic Scale-Up:** Major expansion in cartridge capacity to support GLP-1 pipeline and future contracts, with **new high-speed lines** enhancing efficiency and output. * **Technology & Global Access:** New **BFS line** enables entry into **RoW markets** and captures shift from 3-piece containers, unlocking specialty product opportunities. * **Advanced Isolator Lines:** Planned installation of **vial and combo lines under isolators by 2026** to attract high-value sterile projects and boost capacity. ## C. Lyophilization Utilization * **High Utilization Trends:** Most manufacturing lines run at **80–90% capacity**, with lyophilization expected to reach full utilization in **1–5 years**, driven by strong US volume growth. * **Targeted Capacity Management:** Prefilled syringe and cartridge capacity remains sufficient, with **no near-term capex planned**, allowing focus on higher-growth formats. ## D. Brownfield & Greenfield Projects * **Integrated Expansion Strategy:** Brownfield investments include **new lyophilizers, manufacturing lines, and warehouse capacity**, while **Shamirpet Greenfield site** (adjacent to existing 8 KL facility) expands biologic CDMO footprint. * **CDMO Growth Backed by Contracts:** Biologic capacity tripling is **contract-supported**, signaling strong client traction and expected **high ROCE**, despite lack of quantified returns. * **Cenexi Strategic Leverage:** R&D and manufacturing integration supports products outside Gland’s scope, with **ampoule, vial, and combo line expansions** reinforcing long-term growth confidence. ## E. Fungible Line Flexibility * **Operational Resilience:** **14 crore units of fungible capacity** allow dynamic shift between cartridges, vials, and syringes, de-risking supply and enhancing responsiveness. * **Product Diversification Leverage:** Lines capable of producing **insulin and GLP**, with proven expertise via long-standing **Eli Lilly manufacturing partnership**, enabling cross-product flexibility. --- # 5. R&D & Pipeline Progress ## A. Key Figures * **ANDA Activity:** **9 filed**, **4 approved**, **10 launched** in U.S. (Q3) * R&D Expenses: **₹650 Mn** (5.4% of sales, Q3 FY'26) · ₹1,725 Mn (5.2% of sales, 9M FY'26) ## B. ANDA Filings & Approvals * **Robust Execution:** Strong product development and U.S. market expansion momentum with double-digit filing and launch activity in the quarter. * **Pipeline Depth:** Core pipeline includes **15 products in active development**, split across 505(b)2 and ANDA pathways, anchored in differentiated injectable platforms. * **Near-Term Catalysts:** U.S. approval for Dalba pending, with additional data submitted ahead of **February goal date**; European CMS variations expected to clear within **6 months**, supporting H2 growth. ## C. Co-Development Partnerships * **Strategic Pipeline Expansion:** 15 co-development products targeted for commercialization from **2028**, though launch timing and TAM details remain undisclosed. ## D. Innovation Platforms * **Differentiated R&D Focus:** Pipeline spans **complex injectables**—hormone suspensions, peptides, RTU bags, biosimilars, and specialty platforms—ensuring long-term growth beyond current drivers. * **Sustained Innovation Investment:** R&D remains a strategic differentiator, with current-quarter spend at **4% of revenue**, directed toward advanced delivery systems and platform-based development. * **Capability Building:** Ongoing organic and inorganic investments in talent and leadership to strengthen innovation capacity and support future scalability. --- # 6. Client & Contract Risks ## A. Key Figures * **Milestone Income Decline:** **2%** overall decrease (despite sharp U.S. drop) due to strong European contract contributions ## B. Regulatory Delays * **Project Timeline Slippage:** Contract delays driven by requirements for dedicated compounding facilities, technology transfer, and regulatory variation filings in Europe and other markets. * **Partner-Related Growth Impact:** A major U.S. partner’s product launch delay has negatively affected near-term growth expectations. * **Resilient Milestone Income:** Despite significant drop in U.S. milestone receipts, overall income decline was minimal due to **strong European contract performance**. ## C. Pricing Pressures * **Cost Mitigation Push:** Aggressive internal cost reduction and operational efficiency improvements are underway to win additional U.S. contracts, with recent progress noted. --- # 7. Guidance & Outlook ## A. Key Figures * **Cenexi Revenue:** **€50 Mn** quarterly (in line) · **€200 Mn** annualized base * **Cenexi EBITDA:** **€1 Mn** quarterly * **Revenue Growth YTD:** **12%** for first 9 months (tracking below mid-teens guidance) * Capex (9M FY'26): **₹357 Cr** (INR3,566M) · Full-year FY'26: **~₹250 Cr** (base) + **€25 Mn** (Cenexi) * **Long-Term Capex:** **₹2,000 Cr** planned over next 5 years (base business only) ## B. Revenue Growth Forecast * **Growth Drivers:** Momentum underpinned by new product launches, CDMO contract ramp-ups, and capacity additions, with confidence in **12%-13% full-year growth**. * **Regulatory & Demand Dynamics:** **European demand** expected to offset potential U.S. approval delays for Dalba; **CMS approval timing** remains key upside catalyst. * **Market-Specific Risks:** **GLP-1 demand may outstrip capacity**, but outlook remains conservative due to **patent and pricing uncertainties**. * **Long-Term Optimism:** Management expresses **strong confidence in cartridge line performance** beyond FY28, though no financials provided. ## C. Capex & ROCE Targets * **Expansion Funding:** **₹400+ Cr capex expected next year** as part of ₹2,000 Cr 5-year plan, targeting **asset turnover >3x** from high-value new facilities. * **Investment Discipline:** All projects evaluated against **20% IRR hurdle rate**; CDMO model involves pre-contract capacity build. * **Capital Allocation Clarity:** Entire ₹2,000 Cr capex program is for **base business only**—Cenexi investments excluded. ## D. Cenexi Turnaround Plan * **Confirmed Stabilization:** Cenexi turnaround is on track, with **profitable growth foundation established** via utilization gains, repricing, integration, and operational streamlining. * **Integration Progress:** Full **BD and tech transfer integration with Gland** completed; focus now on closing EBITDA and ROCE gap over **3-year horizon**. * **Performance Drag Acknowledged:** Cenexi acquisition has **diluted group EBITDA margins and ROCE**, making margin restoration a strategic priority. * **Synergy Outlook:** **Steady progress on synergies**, though no quantification provided; long-term value seen through consolidated strategic lens. ## E. Long-Term CAGR Goal * **Strategic Ambition:** Targeting **15% organic CAGR over five years**, excluding inorganics and **incremental joint tender opportunities**. * **Value Creation Framework:** Focus on **scale, earnings quality, and capital productivity** to build a global, innovation-led injectables and CDMO leader. * **Execution Confidence:** Strong results validate strategy, with **inflection expected from 2026** as investments mature.